Impacts of Febuxostat on Cerebral and Cardiovascular Events in Elderly Patients with Hyperuricemia: Post Hoc Analysis of a Randomized Controlled Trial
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Febuxostat shows potential benefits in reducing cardiovascular and cerebrovascular events for elderly patients aged 65-74. However, this uric acid-lowering therapy did not demonstrate similar benefits in patients aged 75 and older.
Area Of Science
- Cardiology
- Geriatrics
- Pharmacology
Background
- Uric acid-lowering therapy, including febuxostat, has shown mixed results regarding cardiovascular and renal benefits.
- Previous meta-analyses indicated no significant advantage of febuxostat in reducing mortality or major adverse events.
- Specific patient populations may still benefit from febuxostat, necessitating further subgroup analyses.
Purpose Of The Study
- To investigate the clinical efficacy of febuxostat in elderly patients with hyperuricemia.
- To stratify the benefits of febuxostat based on age groups (65-74 years vs. ≥75 years).
- To analyze the impact of febuxostat on cerebral, cardiovascular, and renal events in different age strata.
Main Methods
- Post hoc analysis of the Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy (FREED) data.
- Inclusion of 1,070 patients aged 65 years and older with hyperuricemia and cardiovascular risk factors.
- Randomization into febuxostat and non-febuxostat groups, with 36-month monitoring of uric acid levels and primary composite endpoints.
Main Results
- Febuxostat significantly reduced the risk of cerebral and cardiorenovascular events in patients aged 65-74 years.
- No significant benefits of febuxostat were observed in patients aged 75 years and older.
- Greater pre-existing risk factors for cardiorenovascular events were noted in the older age group (≥75 years).
Conclusions
- The effectiveness of febuxostat in preventing adverse cardiovascular and cerebrovascular events is age-dependent.
- Febuxostat may offer benefits for younger elderly patients (65-74 years) with hyperuricemia.
- Clinical use of febuxostat requires careful consideration of individual patient characteristics, particularly age and comorbidities.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...